Russian pharmaceutical company Binnopharm Group (part of AFK Sistema) plans to start supplying Russia with the Chinese analogue of Botox, Lantox, Kommersant writes.
Subscribe to RB.RU on Telegram
RNC Pharma development director Nikolai Bespalov estimated the value of the rights at 4 to 9 million rubles. Binnopharm Group CEO Rustem Muratov estimates that Lantox’s potential sales in Russia will amount to 2-3 billion rubles a year.
Lantox has long been known on the Russian market, but has never occupied a significant market share due to “a number of shortcomings,” said Yulia Frangulova, co-founder of the National Association of SRO Aesthetic Medicine Clinics and director of the clinic. Linline. chain. She believes that the drug can acquire a significant proportion in Russia “only through dumping.”
- Since January 2024, Russian pharmacies have earned 104.4 million rubles from the sale of 11.5 thousand packages of medicines with botulinum toxin. Compared to last year, sales increased by 123%. One of the most famous products is sold under the brand name Botox. It is produced by Allergan (owned by the American Abbvie), which two years ago stopped supplying this medication to Russia.
Author:
Karina Pardaeva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
